FDA frees Amgen's phase 1 obesity asset from clinical trial hold

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants.

The historically tight-lipped Amgen execs remain judicious with what they share, providing few details regarding the matter on a May 1 earnings call.